Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Alliancebernstein L.P.

Alliancebernstein L.P. increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,315,642 shares of the company's stock after buying an additional 268,378 shares during the period. Alliancebernstein L.P. owned 2.30% of Denali Therapeutics worth $67,573,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its position in shares of Denali Therapeutics by 20.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 206,819 shares of the company's stock valued at $6,025,000 after acquiring an additional 34,538 shares during the period. BNP Paribas Financial Markets grew its holdings in Denali Therapeutics by 230.2% in the third quarter. BNP Paribas Financial Markets now owns 27,625 shares of the company's stock valued at $805,000 after purchasing an additional 19,259 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Denali Therapeutics by 12.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,719 shares of the company's stock valued at $866,000 after buying an additional 3,316 shares in the last quarter. Holocene Advisors LP raised its stake in shares of Denali Therapeutics by 65.0% during the 3rd quarter. Holocene Advisors LP now owns 97,447 shares of the company's stock worth $2,839,000 after buying an additional 38,405 shares during the period. Finally, Polar Asset Management Partners Inc. lifted its position in shares of Denali Therapeutics by 70.5% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 41,100 shares of the company's stock valued at $1,197,000 after buying an additional 17,000 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on DNLI shares. Robert W. Baird began coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Bank of America reduced their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, March 10th. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research note on Friday, February 28th. HC Wainwright increased their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics has an average rating of "Moderate Buy" and an average price target of $37.20.

Denali Therapeutics Trading Up 1.6 %

Denali Therapeutics stock traded up $0.19 during mid-day trading on Tuesday, hitting $11.79. The company's stock had a trading volume of 418,867 shares, compared to its average volume of 1,060,181. The stock's fifty day moving average is $17.83 and its two-hundred day moving average is $22.46. The firm has a market capitalization of $1.71 billion, a PE ratio of -4.27 and a beta of 1.58. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, equities analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.